CN106176963A - A kind of Plumula Nelumbinis oral cavity disintegration tablet and preparation method thereof - Google Patents
A kind of Plumula Nelumbinis oral cavity disintegration tablet and preparation method thereof Download PDFInfo
- Publication number
- CN106176963A CN106176963A CN201610580095.8A CN201610580095A CN106176963A CN 106176963 A CN106176963 A CN 106176963A CN 201610580095 A CN201610580095 A CN 201610580095A CN 106176963 A CN106176963 A CN 106176963A
- Authority
- CN
- China
- Prior art keywords
- plumula nelumbinis
- oral cavity
- cavity disintegration
- active component
- disintegration tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000214 mouth Anatomy 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 36
- 239000008187 granular material Substances 0.000 claims abstract description 25
- 239000003086 colorant Substances 0.000 claims abstract description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 23
- 229930195725 Mannitol Natural products 0.000 claims abstract description 23
- 239000000594 mannitol Substances 0.000 claims abstract description 23
- 235000010355 mannitol Nutrition 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 19
- 229920000881 Modified starch Polymers 0.000 claims abstract description 18
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 16
- 239000012567 medical material Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 8
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 description 15
- 230000006793 arrhythmia Effects 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 10
- XCUCMLUTCAKSOZ-JSOSNVBQSA-N Liensinine Natural products C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-JSOSNVBQSA-N 0.000 description 9
- 230000003288 anthiarrhythmic effect Effects 0.000 description 9
- XCUCMLUTCAKSOZ-FIRIVFDPSA-N Liensinine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-FIRIVFDPSA-N 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 7
- -1 methyl Liensinine Chemical compound 0.000 description 7
- 235000021251 pulses Nutrition 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- WUYQEGNOQLRQAQ-CQSZACIVSA-N (+)-pronuciferine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C3C=21)OC)OC)C13C=CC(=O)C=C1 WUYQEGNOQLRQAQ-CQSZACIVSA-N 0.000 description 6
- AJPXZTKPPINUKN-FIRIVFDPSA-N Isoliensinine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-FIRIVFDPSA-N 0.000 description 6
- ZKTMLINFIQCERN-QGZVFWFLSA-O Lotusine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CC[N+]1(C)C)O)OC)C1=CC=C(O)C=C1 ZKTMLINFIQCERN-QGZVFWFLSA-O 0.000 description 6
- AJPXZTKPPINUKN-UHFFFAOYSA-N Isoliensinin Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-UHFFFAOYSA-N 0.000 description 5
- 229940039750 aconitine Drugs 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 239000003416 antiarrhythmic agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 4
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 4
- MIBATSHDJRIUJK-ROJLCIKYSA-N Neferine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-ROJLCIKYSA-N 0.000 description 4
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- WUYQEGNOQLRQAQ-UHFFFAOYSA-N (+)-pronuciferine Natural products C1=2C3=C(OC)C(OC)=CC=2CCN(C)C1CC13C=CC(=O)C=C1 WUYQEGNOQLRQAQ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 206010047302 ventricular tachycardia Diseases 0.000 description 3
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical group C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 2
- WZRCQWQRFZITDX-UHFFFAOYSA-N (RS)-norcoclaurine Chemical compound C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- WZRCQWQRFZITDX-AWEZNQCLSA-N Norcoclaurine Natural products C1=CC(O)=CC=C1C[C@H]1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-AWEZNQCLSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 2
- KBGKQZVCLWKUDQ-UHFFFAOYSA-N luteolin-glucoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC2=C1C(=O)C=C(C=1C=C(O)C(O)=CC=1)O2 KBGKQZVCLWKUDQ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229930001545 pronuciferine Natural products 0.000 description 2
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 2
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010023832 Florigen Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- 235000016357 Mirtillo rosso Nutrition 0.000 description 1
- MIBATSHDJRIUJK-UHFFFAOYSA-N Neferine Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-UHFFFAOYSA-N 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000001261 florigenic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical group 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of Plumula Nelumbinis oral cavity disintegration tablet and preparation method thereof, it is with Plumula Nelumbinis as crude drug, and its preparation method is: take the active component of Plumula Nelumbinis, it is dried, beat powder, add beta cyclodextrin, mannitol by weight, low-substituted hydroxypropyl cellulose, pregelatinized Starch, magnesium stearate, coloring agent, correctives, process for producing granula makes granule routinely, and after granulate, disintegrating tablet made by tabletting.
Description
Technical field
The present invention relates to drug world, be specifically related to a kind of Plumula Nelumbinis oral cavity disintegration tablet and preparation method thereof.
Background technology
Arrhythmia refers to tachycardia that the abnormal or exciting conductive impairment of the self-disciplining of heart causes, the most slow, and the rhythm of the heart is not
A neat or class disease of ectopic cardiac rhythm.Its clinical manifestation is paroxysmal cardiopalmus, chest pain, dizziness, pareordia sense of discomfort, feel oppressed,
Out of breath, hands and feet coolness and fainting, the even symptom such as obnubilation.There is the small part arrhythmic patients can be asymptomatic, only electrocardio
Figure changes.Its sickness rate and case fatality rate are the highest, constitute about the 11% of natural death number.According to statistics, China there are about 60 every year
Ten thousand people die from sudden cardiac death, and wherein 90% is to be caused by malignant arrhythmia, therefore becomes for ARR treatment
Numerous medical personal focus of attention all the time.
Clinically ARR western medicine is had the features such as rapid, the determined curative effect of effect, but side effect is relatively big, and
And in place of several equal Shortcomings of class antiarrhythmic drug used clinically at present, during such as treatment arrhythmia, lure the most again
Sending out arrhythmia, incidence rate is up to more than 10%；The most easily induce conduction block and drug induccd heart failure simultaneously, and to some intractable
Arrhythmia is invalid.
The traditional Chinese medical science is the most on the books as far back as Huangdi's Internal Classics one book to ARR understanding, such as " a Plain Questions normal person meteorology opinion piece "
Have: " people one exhales arteries and veins one to move, and one inhales arteries and veins one moves, and says few gas.... people one exhales arteries and veins four to move above saying extremely ", the contained arteries and veins of Pulse Classic comes again
" first the least, irregularity in frequency of pulse beat " " such as fiber crops bean hitter " etc., depict ARR pulse condition the most visually.Later age, doctor, passed through
Clinical practice, is described as pulse condition knot, generation, promotees, count, slow etc. is all.
Motherland's medical science is thought, if suffering from the disease such as the thoracic obstruction, pained, gastral cavity is vexed, cough with asthma, the obstruction of heart-QI for a long time, all can cause yang-energy virtual loss heart arteries and veins and losing
In Wen Yun, deficiency of YIN-blood, it is flourish and be disease that heart arteries and veins loses network, thus cause occurring slow, count, promote, tie, generation, the most serious is exhausted
The abnormal pulse such as arteries and veins, these pulse conditions all can reflect arrhythmia.Differentiation of tcm, with vigorate qi and replenish the blood, tranquilizing by nourishing the heart is primary disease
Therapeutic Principle.
In recent years, research finds the phenol biology total alkali extracted from prepared slices of Chinese crude drugs Plumula Nelumbinis, such as liensinine, methyl Plumula Nelumbinis
Alkali, isoliensinine etc. have significant antiarrhythmic effect.Therefore, bioavailability and Plumula Nelumbinis in order to improve medicine are steady
Qualitative, in conjunction with the compliance of patients with arrhythmia treatment, facilitate patient to take simultaneously, Plumula Nelumbinis is prepared as solid immediate release agent
Type oral instant-dissolving tablet.
Summary of the invention
It is an object of the invention to provide a kind of Plumula Nelumbinis oral cavity disintegration tablet；
It is a further object of the present invention to provide the preparation method of a kind of Plumula Nelumbinis oral cavity disintegration tablet.
It is an object of the invention to by following technical scheme realization:
Plumula Nelumbinis oral cavity disintegration tablet of the present invention, it is to be prepared from by the raw material of following weight portion:
Plumula Nelumbinis 5-50 part, beta-schardinger dextrin-2-20 part, mannitol 5-25 part, low-substituted hydroxypropyl cellulose 5-30 part, in advance
Gelling starch 5-15 part, magnesium stearate 0.1-3 part, coloring agent 0.1-1 part, correctives 0.1-1 part.
Preferably, it is to be prepared from by the raw material of following weight portion:
Plumula Nelumbinis 15-30 part, beta-schardinger dextrin-5-15 part, mannitol 15-25 part, low-substituted hydroxypropyl cellulose 20-30 part,
Pregelatinized Starch 10-15 part, magnesium stearate 0.1-1 part, coloring agent 0.3-0.8 part, correctives 0.3-0.8 part.
The following is primary efficacy and the pharmacological action of Plumula Nelumbinis of the present invention:
Plumula Nelumbinis, for the green embryo in the middle of the mature seed of nymphaeaceae plant lotus Nelumbo nucifera Gaertn.
Root, i.e. Plumula Nelumbinis.Nature and flavor are bitter, cold, are included into the heart, kidney channel.Plumula Nelumbinis has clearing away heart-fire for tranquillization, restoring normal coordination between the heart and kidney, effect of unsmoothing the sperm and stopping bleeding, uses
In heat attacking the pericardium, unconsciousness and delirium, disarmony between the heart and kidney, the diseases such as seminal emission, heat in blood haematemesis of having a sleepless night.Recording according to " book on Chinese herbal medicine is the newest ", Plumula Nelumbinis is " clear
Heart-fire, suppressing the hyperactive liver fire, purgation of spleen excess fire, drop lung-fire, relieving restlessness of relieving summer heat, promoting the production of body fluid to quench thirst, control mesh red and swollen ".Plumula Nelumbinis is " Chinese Pharmacopoeia " 2015
Version is recorded, main product Hunan, Hubei, Fujian, Jiangsu, zhejiang and other places.
Containing multiple alkaloid in Plumula Nelumbinis: liensinine (liensinine), isoliensinine (isoliensinine), methyl
Liensinine (neferine), C19H23NO3 (lotusine), methyl-corypalline alkali (methye-corypalline), Folium Nelumbinis
Alkali (Nuciferine), pronuciferine (+)-Pronuciferine (Pronuciferine) and demethyl coclaurine (demethylcoclaurine), Cornu Bovis seu Bubali
Florigen (Lotusine), also gets amorphism alkaloid Nn-9, again containing galuteolin from separation liensinine mother solution
(Galuteolin), the flavonoid such as hyperin (Hyperin), globulariacitrin (Rutin).In addition, in Plumula Nelumbinis possibly together with
The trace element such as water soluble polysaccharide composition and zinc, copper, ferrum, calcium, magnesium, sodium, potassium, nickel, manganese, cadmium.
Modern plants chemical research shows in Plumula Nelumbinis that phenol alkaloid position is mainly containing liensinine, (-)-Neferine, different
Liensinine.Modern pharmacological research shows, Plumula Nelumbinis total alkaloids and monomer all have have widely arrhythmia, resist myocardial ischemia
With the effect of blood pressure lowering, it is primarily adapted for use in treatment arrhythmia and myocardial ischemia.Its antiarrhythmic effect is better than conventional medicament
Kui Nining, function of resisting myocardial ischemia and diltiazem are suitable, additionally, also have blood pressure lowering, antioxidation and for glycosuria
The preventing and treating of disease syndrome.
Plumula Nelumbinis alkaloid main component liensinine, isoliensinine, (-)-Neferine, the pharmacological action of C19H23NO3 and
Its mechanism is as follows:
1, liensinine (Lien) has preferable antiarrhythmic effect, and its mechanism of action may be with retardance Na+, Ca2+, K+
Transmembrane transport relevant.
2, (-)-Neferine (Nef) can suppress the self-disciplining of sinuatrial node slow reacting cell and delay Atrioventricular Conduction, has maincenter
Property antiarrhythmic effect.For Ia class antiarrhythmic drug, its antiarrhythmic mechanism and quinidine or procaine acyl
Amine is similar.
3, C19H23NO3 (lotus, lotusine) is water-soluble alkaloid in Plumula Nelumbinis.Lot dose-dependently increases
The contractility of isolated myocardium and effect are better than amrinone (Am) and papaverine (Pa).But not there is antiarrhythmic effect.Lot
Similar to phosphodiesterase III inhibitor to the feature of hemodynamic effects.
4, α receptor is had more obvious blocking effect interior calcium that this receptor can be suppressed to cause to release by isoliensinine (Iso)
Put and extrinsic AGB stars.Pulse dependent calcium channel is also had retardation.Transient slight blood pressure lowering and the not normal effect of the anti-heart of Iso can
Can be the most relevant with these.
Present invention also offers the preparation method of the active component of Plumula Nelumbinis, the method is to use water to carry or lower alcohol extract
Extraction is prepared from.Concrete preparation method is as follows:
Scheme one: take Plumula Nelumbinis, extracting in water 2-3 time, each amount of water is equivalent to 5-12 times of medical material gross weight, every time
Extraction time is 1-3 hour, united extraction liquid, filters, and when filtrate is concentrated into 25 DEG C, relative density is the thick paste of 1.20-1.40,
Obtain described active component.
Scheme two: take Plumula Nelumbinis, extracting in water 2-3 time, each amount of water is equivalent to 5-12 times of medical material gross weight, every time
Extraction time is 1-3 hour, united extraction liquid, filters, takes supernatant after standing, and when filtrate is concentrated into 25 DEG C, relative density is
The clear paste of 1.05-1.20, adds ethanol, and making alcohol content is 40%-70%, stands 6-24 hour, filters, and filtrate is concentrated into 25 DEG C
Time relative density be the thick paste of 1.20-1.40, obtain described active component.
Scheme three: take Plumula Nelumbinis, adds alcohol extraction 2-3 time, and each alcohol adding amount is equivalent to 5-12 times of medical material gross weight, every time
Extraction time is 1-3 hour, united extraction liquid, filters, and when filtrate is concentrated into 25 DEG C, relative density is the thick paste of 1.20-1.40,
Obtain described active component.
Scheme four: take Plumula Nelumbinis, adds alcohol extraction 2-3 time, and each alcohol adding amount is equivalent to 5-12 times of medical material gross weight, every time
Extraction time is 1-3 hour, united extraction liquid, filters, and when filtrate is concentrated into 25 DEG C, relative density is the clear paste of 1.05-1.20,
Adding water, making water content is 40%-70%, stands 6-24 hour, filters, and when filtrate is concentrated into 25 DEG C, relative density is 1.20-
The thick paste of 1.40, obtains described active component.
Described lower alcohol extract is methanol, ethanol, normal propyl alcohol, isopropanol, 1-propenol-3, n-butyl alcohol, isobutanol, two grades of fourths
One or more mixing in alcohol, tertiary butyl alcohol.
The coloring agent told and correctives include but not limited to following:
Coloring agent: amaranth, carmine, erythrosine, the reddest, lemon yellow, sunset yellow, indigo, light blue, beet red, lac
Red, red pigment of cowberry, capsanthin, red rice are red.
Correctives: sucrose, simple syrup, syrupus aromaticus, stevioside, glycerol, sorbitol, mannitol, saccharin sodium, A Sipa
Smooth.
Present invention also offers the preparation method of a kind of Plumula Nelumbinis oral cavity disintegration tablet:
Method 1: take the active component of the Plumula Nelumbinis of above-mentioned gained, adds beta-schardinger dextrin-, mannitol, low replacement by weight
Hydroxypropyl cellulose, pregelatinized Starch, magnesium stearate, coloring agent, correctives, process for producing granula makes granule routinely,
After granulate, disintegrating tablet made by tabletting.
Method 2: take the active component of the Plumula Nelumbinis of above-mentioned gained, is dried, beats powder, add beta-schardinger dextrin-by weight, sweet
Dew alcohol, low-substituted hydroxypropyl cellulose, pregelatinized Starch, magnesium stearate, coloring agent, correctives, routinely granule preparation side
Method makes granule, and after granulate, disintegrating tablet made by tabletting.
Plumula Nelumbinis oral cavity disintegration tablet of the present invention is effective ingredient in Chinese preparation, and principle active component physicochemical property is clear
Chu, the mechanism of action is clear and definite, and taking dose is little, and active component content is high, and safety range is wide, meets and prepares dosage form novel, efficient
Primary condition.Plumula Nelumbinis oral cavity disintegration tablet is rapid due to release, and medicine is directly entered body is followed by oral cavity, sublingual mucosal absorption
Ring, decreases the gastrointestinal tract destruction to medicine, decreases liver first-pass effect, therefore the most rapid-action compared with conventional tablet, raw
Thing availability is also remarkably improved, and meets tcm emergency ARR clinical application requirement.Compared with injection, this dosage form has
Having volume little, good stability, drug absorption is fast, takes and the advantage such as easy to carry.
The present invention is directed to arrhythmia clinical treatment present situation, overcome the deficiency of existing treatment antiarrhythmic medicament preparation,
Under guidance of traditional Chinese medicine theory, actively use modern Chinese medicine pharmaceutical technology, on existing Research foundation, both designed and developed into further
Meet tcm clinical practice Therapy characteristics, there is again the pure Chinese medicinal preparation quick-acting, efficient of Modern preparations feature.The rhythm of the heart is lost by the present invention
Normal treatment and oral cavity disintegration tablet technology of preparing produce important and active influence, will produce huge social benefit and warp simultaneously
Ji interests.
A kind of Plumula Nelumbinis oral cavity disintegration tablet that the present invention provides has the advantage that
1, the Plumula Nelumbinis oral cavity disintegration tablet that the present invention provides is not required to water delivery service, is put in oral cavity disintegrate or melt in about 15～30 seconds
Changing, bad for some function of deglutition and water intaking inconvenience patient is especially suitable.
2, the Plumula Nelumbinis oral cavity disintegration tablet onset that the present invention provides is rapid, can reduce medicine " first pass effect " simultaneously.
3, oral cavity disintegration tablet is a kind of new oral solid preparation occurred in drugs consumption market in recent years, unique with it
Superiority increasingly liked by patient, the present invention provide Plumula Nelumbinis oral cavity disintegration tablet there is wide market prospect.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustrating
The present invention rather than limitation of the present invention.The simple modifications that the present invention is carried out by the essence according to the present invention broadly falls into the present invention
Claimed scope.Except as otherwise noted, the percent of the amount of alcohol in the present invention is percentage by volume, and v/v represents solution
Volume ratio.
Embodiment 1
Plumula Nelumbinis 50g, beta-schardinger dextrin-2g, mannitol 5g, low-substituted hydroxypropyl cellulose 30g, pregelatinized Starch 5g, stearic
Acid magnesium 3g, coloring agent 1g, correctives 1g.
Taking Plumula Nelumbinis, crushed after being dried becomes coarse powder, extracting in water 3 times, and three amount of water are the most respectively when in medical material gross weight
12 times, 8 times, 5 times, each extraction time is respectively 3 hours, 2 hours, 1 hour, united extraction liquid, filter, filtrate is concentrated into
When 25 DEG C, relative density is the thick paste of 1.40, obtains the active component of Plumula Nelumbinis.
Take the active component of Plumula Nelumbinis, add beta-schardinger dextrin-, mannitol, low-substituted hydroxypropyl cellulose, pre-glue by weight
Changing starch, magnesium stearate, coloring agent, correctives, process for producing granula makes granule routinely, and after granulate, disintegrate made by tabletting
Sheet.
Embodiment 2
Plumula Nelumbinis 5g, beta-schardinger dextrin-20g, mannitol 25g, low-substituted hydroxypropyl cellulose 5g, pregelatinized Starch 15g, firmly
Fatty acid magnesium 0.1g, coloring agent 0.1g, correctives 0.1g.
Taking Plumula Nelumbinis, crushed after being dried becomes coarse powder, and extracting in water 2 times, each amount of water is respectively equivalent to medical material gross weight
10 times, 6 times, each extraction time is 2 hours, united extraction liquid, filter, take supernatant after standing, filtrate is concentrated into 25 DEG C
Time relative density be the clear paste of 1.05, add ethanol, making alcohol content is 40%, stands 24 hours, filtration, filtrate is concentrated into 25 DEG C
Time relative density be the thick paste of 1.20, obtain the active component of Plumula Nelumbinis.
Taking the active component of Plumula Nelumbinis, be dried, beat powder, add beta-schardinger dextrin-, mannitol by weight, low substituted hydroxy-propyl is fine
Dimension element, pregelatinized Starch, magnesium stearate, coloring agent, correctives, process for producing granula makes granule routinely, presses after granulate
Sheet makes disintegrating tablet.
Embodiment 3
Plumula Nelumbinis 15g, beta-schardinger dextrin-15g, mannitol 15g, low-substituted hydroxypropyl cellulose 20g, pregelatinized Starch 10g,
Magnesium stearate 1g, coloring agent 0.3g, correctives 0.3g.
Taking Plumula Nelumbinis, crushed after being dried becomes coarse powder, and extracting in water 3 times, each amount of water is respectively equivalent to medical material gross weight
12 times, 8 times, 6 times, each extraction time is respectively 3 hours, 2 hours, 1 hour, united extraction liquid, filter, take after standing
Clear liquid, when filtrate is concentrated into 25 DEG C, relative density is the clear paste of 1.20, adds ethanol, and making alcohol content is 70%, stands 6 hours,
Filtering, when filtrate is concentrated into 25 DEG C, relative density is the thick paste of 1.40, obtains the active component of Plumula Nelumbinis.
Taking the active component of Plumula Nelumbinis, be dried, beat powder, add beta-schardinger dextrin-, mannitol by weight, low substituted hydroxy-propyl is fine
Dimension element, pregelatinized Starch, magnesium stearate, coloring agent, correctives, process for producing granula makes granule routinely, presses after granulate
Sheet makes disintegrating tablet.
Embodiment 4
Plumula Nelumbinis 20g, beta-schardinger dextrin-10g, mannitol 20g, low-substituted hydroxypropyl cellulose 25g, pregelatinized Starch 15g,
Magnesium stearate 1g, coloring agent 0.8g, correctives 0.8g.
Taking Plumula Nelumbinis, crushed after being dried becomes coarse powder, adds alcohol extraction 3 times, and each alcohol adding amount is equivalent to the 12 of medical material gross weight
Times, 10 times, 6 times, each extraction time is 3 hours, 2 hours, 1 hour, united extraction liquid, filter, when filtrate is concentrated into 25 DEG C
Relative density is the thick paste of 1.30, obtains the active component of Plumula Nelumbinis.
Take the active component of Plumula Nelumbinis, add beta-schardinger dextrin-, mannitol, low-substituted hydroxypropyl cellulose, pre-glue by weight
Changing starch, magnesium stearate, coloring agent, correctives, process for producing granula makes granule routinely, and after granulate, disintegrate made by tabletting
Sheet.
Embodiment 5
Plumula Nelumbinis 40g, beta-schardinger dextrin-5g, mannitol 10g, low-substituted hydroxypropyl cellulose 20g, pregelatinized Starch 8g, firmly
Fatty acid magnesium 2g, coloring agent 0.5g, correctives 0.5g.
Taking Plumula Nelumbinis, crushed after being dried becomes coarse powder, adds alcohol extraction 2 times, and each alcohol adding amount is equivalent to the 10 of medical material gross weight
Times, 8 times, each extraction time is 2 hours, united extraction liquid, filter, when filtrate is concentrated into 25 DEG C relative density be 1.40 thick
Cream, obtains the active component of Plumula Nelumbinis.
Taking the active component of Plumula Nelumbinis, be dried, beat powder, add beta-schardinger dextrin-, mannitol by weight, low substituted hydroxy-propyl is fine
Dimension element, pregelatinized Starch, magnesium stearate, coloring agent, correctives, process for producing granula makes granule routinely, presses after granulate
Sheet makes disintegrating tablet.
Embodiment 6
Plumula Nelumbinis 10g, beta-schardinger dextrin-8g, mannitol 20g, low-substituted hydroxypropyl cellulose 25g, pregelatinized Starch 12g, firmly
Fatty acid magnesium 1.5g, coloring agent 0.5g, correctives 0.8g.
Taking Plumula Nelumbinis, crushed after being dried becomes coarse powder, adds alcohol extraction 2 times, and each alcohol adding amount is equivalent to the 8 of medical material gross weight
Times, each extraction time is 2 hours, united extraction liquid, filters, and when filtrate is concentrated into 25 DEG C, relative density is the clear paste of 1.20,
Adding water, making water content is 40%, stands 24 hours, filters, and when filtrate is concentrated into 25 DEG C, relative density is the thick paste of 1.40, i.e.
Obtain the active component of Plumula Nelumbinis.
Taking the active component of Plumula Nelumbinis, be dried, beat powder, add beta-schardinger dextrin-, mannitol by weight, low substituted hydroxy-propyl is fine
Dimension element, pregelatinized Starch, magnesium stearate, coloring agent, correctives, process for producing granula makes granule routinely, presses after granulate
Sheet makes disintegrating tablet.
Embodiment 7
Plumula Nelumbinis 20g, beta-schardinger dextrin-10g, mannitol 15g, low-substituted hydroxypropyl cellulose 10g, pregelatinized Starch 15g,
Magnesium stearate 2.5g, coloring agent 0.3g, correctives 0.5g.
Taking Plumula Nelumbinis, crushed after being dried becomes coarse powder, adds alcohol extraction 3 times, and each alcohol adding amount is equivalent to the 12 of medical material gross weight
Times, 10 times, 5 times, each extraction time is 3 hours, 2 hours, 1 hour, united extraction liquid, filter, when filtrate is concentrated into 25 DEG C
Relative density is the clear paste of 1.05, adds water, and making water content is 70%, stands 6 hours, filters, and filtrate is concentrated into 25 DEG C of phases
It is the thick paste of 1.20 to density, obtains the active component of Plumula Nelumbinis.
Take the active component of Plumula Nelumbinis, add beta-schardinger dextrin-, mannitol, low-substituted hydroxypropyl cellulose, pre-glue by weight
Changing starch, magnesium stearate, coloring agent, correctives, process for producing granula makes granule routinely, and after granulate, disintegrate made by tabletting
Sheet.Pharmacodynamic experiment
1 experimental example Plumula Nelumbinis oral cavity disintegration tablet antiarrhythmic experimentation
1.1 laboratory animal
SD rat, Mus age 8～12 weeks, body weight 280 ± 10g, Guangdong Medical Lab Animal Center provide, male and female divide cage
Freely raise, be randomly divided into 6 groups: negative control group, mexiletine group and 3 dosage Plumula Nelumbinis oral cavity disintegration tablet groups.
1.2 medicines and dosage
(1) test medicine: Plumula Nelumbinis oral cavity disintegration tablet described in the embodiment of the present invention 5, is prepared from by Plumula Nelumbinis medical material, makes
It is configured to desired concn with front drinking water.Basic, normal, high dosage is respectively: 0.4g/kg, 0.8g/kg, 1.6g/kg.
(2) positive drug: mexiletine, each dosage is 50mg/kg.
(3) negative medicine: the auxiliaries removing Plumula Nelumbinis in substrate instant component forms.
Administering mode: gastric infusion, every day 2 times, the upper and lower noon is each once.Continue 7 days.
1.3 statistical analysis
Data result is usedRepresent, use the ANOVA variance analysis of SPSS17.0 statistical software to carry out significance of difference inspection
Test.1.4 experimental techniques and result
1.4.1 laboratory animal modeling and administration
Aconitine induced rat arrhythmia is tested.Negative control group gavage (ig) gives equal-volume bare substrate 0.6g/
Kg, Plumula Nelumbinis oral cavity disintegration tablet basic, normal, high dosage group respectively organize ig respectively give 0.4,0.8,1.6g/kg, positive group ig give U.S.
West rule 50mg/kg, is administered 7 days.After last is administered 30 minutes, lumbar injection (ip) urethane 1.2g/kg anaesthetizes, and faces upward position and fixes,
Lead physiological signal record analysis system with six to monitor continuously, and record electrocardiogram (ECG) II and lead ECG.After electrocardiogram is stable,
Quickly Lingual vessels injection (iv) aconitine 200 μ g/kg (having noted in 0.01%, 0.2ml/100g, 3s), occurs ventricular premature contraction in succession
(Ventricular prem ature beat, VP), ventricular tachycardia (Vent ricular tachycardia, VT), and
Develop into stable biphasic or bipolar type arrhythmia, to ventricular fibrillation (Vent ricular fibrillation, VF) and heart occur
Stop fight (Cardiac arrest, CA), following experimental index in recording 60 minutes: not normal time of occurrence, the not normal persistent period, extensive
Multiple time of occurrence, normal duration (initial time, by injection, calculates each section of merging summation occurred).
1.4.2 Plumula Nelumbinis oral cavity disintegration tablet anti-aconitine induction SD rat ventricular result
Table 1 aconitine each group of SD rat ventricular experimental result of induction
Compared with negative control group, P < 0.05
1.5 conclusion
The arrhythmia of Aconitine Induced is likely due to the most excited cardiac muscle, makes Myocardial Na+Channel opener, accelerates cardiac muscle
Cell Na+Caused by interior stream, it is chiefly to facilitate membrane depolarization, accelerates pacemaker self-disciplining, shorten refractory stage, thus cause room
Property and the arrhythmia such as supraventricular ectopic rhythm and ventricular tachycardia.Test result indicate that, Plumula Nelumbinis oral cavity disintegration tablet is permissible
Extending arrhythmia time of occurrence, shorten the not normal persistent period, extend normal duration, Plumula Nelumbinis oral cavity disintegration tablet has one
Fixed Antiarrhythmic Effect.
Although, used general explanation, detailed description of the invention and test, the present invention made detailed retouching
Stating, but on the basis of the present invention, can make some modifications or improvements it, this is apparent to those skilled in the art
's.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, belong to claimed
Scope.
Claims (10)
1. a Plumula Nelumbinis oral cavity disintegration tablet, it is characterised in that it is to be prepared from by the raw material of following weight portion:
Plumula Nelumbinis 5-50 part, beta-schardinger dextrin-2-20 part, mannitol 5-25 part, low-substituted hydroxypropyl cellulose 5-30 part, pregelatinated
Starch 5-15 part, magnesium stearate 0.1-3 part, coloring agent 0.1-1 part, correctives 0.1-1 part.
2. Plumula Nelumbinis oral cavity disintegration tablet as claimed in claim 1, it is characterised in that it is to be prepared by the raw material of following weight portion
: Plumula Nelumbinis 15-30 part, beta-schardinger dextrin-5-15 part, mannitol 15-25 part, low-substituted hydroxypropyl cellulose 20-30 part,
Pregelatinized Starch 10-15 part, magnesium stearate 0.1-1 part, coloring agent 0.3-0.8 part, correctives 0.3-0.8 part.
3. Plumula Nelumbinis oral cavity disintegration tablet as claimed in claim 1 or 2, it is characterised in that the active component of Plumula Nelumbinis is to use water
Carry or lower alcohol extract extracts and is prepared from.
4. Plumula Nelumbinis oral cavity disintegration tablet as claimed in claim 3, it is characterised in that the active component of Plumula Nelumbinis is by following
Method is prepared from: take Plumula Nelumbinis, extracting in water 2-3 time, and each amount of water is equivalent to 5-12 times of medical material gross weight, every time
Extraction time is 1-3 hour, united extraction liquid, filters, and when filtrate is concentrated into 25 DEG C, relative density is the thick paste of 1.20-1.40,
Obtain described active component.
5. Plumula Nelumbinis oral cavity disintegration tablet as claimed in claim 3, it is characterised in that the active component of Plumula Nelumbinis is by following
Method is prepared from: take Plumula Nelumbinis, extracting in water 2-3 time, and each amount of water is equivalent to 5-12 times of medical material gross weight, every time
Extraction time is 1-3 hour, united extraction liquid, filters, takes supernatant after standing, and when filtrate is concentrated into 25 DEG C, relative density is
The clear paste of 1.05-1.20, adds ethanol, and making alcohol content is 40%-70%, stands 6-24 hour, filters, when filtrate is concentrated into 25 DEG C
Relative density is the thick paste of 1.20-1.40, obtains described active component.
6. Plumula Nelumbinis oral cavity disintegration tablet as claimed in claim 3, it is characterised in that the active component of Plumula Nelumbinis is by following
Method is prepared from: take Plumula Nelumbinis, adds alcohol extraction 2-3 time, and each alcohol adding amount is equivalent to 5-12 times of medical material gross weight, every time
Extraction time is 1-3 hour, united extraction liquid, filters, and when filtrate is concentrated into 25 DEG C, relative density is the thick paste of 1.20-1.40,
Obtain described active component.
7. Plumula Nelumbinis oral cavity disintegration tablet as claimed in claim 3, it is characterised in that the active component of Plumula Nelumbinis is by following
Method is prepared from: take Plumula Nelumbinis, adds alcohol extraction 2-3 time, and each alcohol adding amount is equivalent to 5-12 times of medical material gross weight, every time
Extraction time is 1-3 hour, united extraction liquid, filters, and when filtrate is concentrated into 25 DEG C, relative density is the clear paste of 1.05-1.20,
Adding water, making water content is 40%-70%, stands 6-24 hour, filters, and when filtrate is concentrated into 25 DEG C, relative density is 1.20-
1.40 thick paste, obtain described active component.
8. Plumula Nelumbinis oral cavity disintegration tablet as claimed in claim 3, it is characterised in that described lower alcohol extract is methanol, second
One or more in alcohol, normal propyl alcohol, isopropanol, 1-propenol-3, n-butyl alcohol, isobutanol, secondary butanol, tertiary butyl alcohol mix
Close.
9. the preparation method of a Plumula Nelumbinis oral cavity disintegration tablet, it is characterised in that take the activity of Plumula Nelumbinis described in claim 3
Composition, adds beta-schardinger dextrin-, mannitol, low-substituted hydroxypropyl cellulose, pregelatinized Starch, magnesium stearate, coloring by weight
Agent, correctives, process for producing granula makes granule routinely, and after granulate, disintegrating tablet made by tabletting.
10. the preparation method of a Plumula Nelumbinis oral cavity disintegration tablet, it is characterised in that take the work of Plumula Nelumbinis described in claim 3
Property composition, be dried, beat powder, add beta-schardinger dextrin-by weight, mannitol, low-substituted hydroxypropyl cellulose, pregelatinized Starch, firmly
Fatty acid magnesium, coloring agent, correctives, process for producing granula makes granule routinely, and after granulate, disintegrating tablet made by tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610580095.8A CN106176963A (en) | 2016-07-22 | 2016-07-22 | A kind of Plumula Nelumbinis oral cavity disintegration tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610580095.8A CN106176963A (en) | 2016-07-22 | 2016-07-22 | A kind of Plumula Nelumbinis oral cavity disintegration tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106176963A true CN106176963A (en) | 2016-12-07 |
Family
ID=57491218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610580095.8A Pending CN106176963A (en) | 2016-07-22 | 2016-07-22 | A kind of Plumula Nelumbinis oral cavity disintegration tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176963A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110353073A (en) * | 2019-08-27 | 2019-10-22 | 广东工业大学 | A kind of decompression hard candy and preparation method thereof |
-
2016
- 2016-07-22 CN CN201610580095.8A patent/CN106176963A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 朱珠: "莲心含片制备工艺研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110353073A (en) * | 2019-08-27 | 2019-10-22 | 广东工业大学 | A kind of decompression hard candy and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| CN101230003B (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| CN101278939B (en) | Medicament composition for curing cardiovascular and cerebrovascular diseases and method of preparing the same | |
| CN101284050A (en) | Corydalis tuber water-soluble part medicine and preparation method and application thereof | |
| JP6369931B2 (en) | Anti-obesity agent | |
| CN102872227A (en) | Gelan Xinning soft capsule for treating coronary disease and angina and preparation method thereof | |
| CN106176963A (en) | A kind of Plumula Nelumbinis oral cavity disintegration tablet and preparation method thereof | |
| CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
| CN105056192A (en) | Traditional Chinese medicine composition for treating myocardial infarction and application thereof | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101856357B (en) | Application of rotundic acid in preparing medicines for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN113476526B (en) | A Chinese medicinal composition for treating atrial fibrillation, and its preparation method | |
| CN102120000B (en) | Composition of effective parts of traditional Chinese medicine preparation for resisting Coxsackie virus B and preparation method thereof | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN101947299B (en) | Medicinal composition for treating coronary heart disease | |
| CN100546637C (en) | A kind of Chinese medicine composition for the treatment of coronary heart disease and preparation method thereof | |
| CN101696166B (en) | Preparation method for danshen root salvianolic acid A | |
| CN110664922A (en) | Composition with chloasma removing function and preparation method and application thereof | |
| CN104524139A (en) | Allium wallichii extract and application thereof | |
| CN108938718A (en) | A kind of preparation method of Chinese medicine composition and its preparation for treating headstroke | |
| CN101491594A (en) | Soft-capsules for treating bronchitis and preparation method thereof | |
| CN102552481A (en) | Traditional Chinese medicinal composition with effects of smoothing collaterals and lowering blood pressure and preparation method thereof | |
| CN113181205B (en) | Pharmaceutical composition comprising NMN and use thereof | |
| CN109248201B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating arrhythmia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161207 |
|
| WD01 | Invention patent application deemed withdrawn after publication |